NEWS & EVENTS
Challenging Japan's Most Rigorous Medical System Tests! Biomedica Successfully Passes Two IHE International Interoperability Tests at Once, Leading Taiwan's AI Medical Technology onto the Global Stage.
November 19,2025
Challenging Japan’s Most Rigorous Medical System Test!
Biomedica Passes Dual IHE International Interoperability Tests in One Go — Leading Taiwan’s AI Healthcare to Global Integration
Source: Global Bio & Investment → https://lnkd.in/g9etiaaK
Taiwan’s AI medical technology continues to shine on the international stage! Biomedica successfully passed two major interoperability tests — DICOM SWF (Scheduled Workflow) and FHIR MHD (Mobile Access to Health Documents) — at the recently concluded Asia-Pacific IHE Connectathon 2025. This remarkable achievement demonstrates Biomedica’s exceptional system integration capabilities and adherence to global standards. More importantly, it signifies Taiwan’s solid position in AI medical imaging and smart healthcare interoperability, fully aligned with global advancements.
First Taiwan–Japan–Korea Joint Test in 20 Years — A Milestone for Asia-Pacific Medical Interoperability
Biomedica Achieves Dual Certification — Demonstrating Global AI Healthcare Competence
DICOM SWF (Scheduled Workflow)
This test focuses on the integrity and accuracy of the entire imaging workflow — from patient registration and image acquisition to report generation and data return. Biomedica collaborated with IHE Japan, DaiKon, and FUJIFILM in rigorous cross-verification tests and successfully passed all evaluation items, earning international interoperability certification.
FHIR MHD (Mobile Access to Health Documents)
This next-generation standard emphasizes cross-platform, real-time, and secure medical document exchange. Although Biomedica was not originally scheduled to participate in this category, its team proactively applied on-site to take on the challenge. Within a short timeframe, the engineers completed system integration, data format adjustments, and API connections — ultimately passing joint testing with DaiKon, IBM, and Soft Max. The success demonstrated the team’s technical agility and strong engineering depth in AI healthcare.
AIXA AI for Osteoporosis & Sarcopenia — Driving International Clinical Adoption
Biomedica revealed that its AIXA AI-powered medical imaging analysis system for osteoporosis and sarcopenia diagnosis is currently under regulatory review in Japan and South Korea. Using only a single X-ray image, AIXA can analyze bone density and muscle mass within six seconds, helping physicians quickly assess osteoporosis and sarcopenia risks, enabling early prevention and improving diagnostic efficiency.
With the successful results from the Taiwan–Japan–Korea joint testing, Biomedica is now poised to directly interface with hospital systems in Japan and South Korea, establishing an international clinical model for AI-based osteoporosis and muscle loss screening.
Biomedica Passes Dual IHE International Interoperability Tests in One Go — Leading Taiwan’s AI Healthcare to Global Integration
Source: Global Bio & Investment → https://lnkd.in/g9etiaaK
Taiwan’s AI medical technology continues to shine on the international stage! Biomedica successfully passed two major interoperability tests — DICOM SWF (Scheduled Workflow) and FHIR MHD (Mobile Access to Health Documents) — at the recently concluded Asia-Pacific IHE Connectathon 2025. This remarkable achievement demonstrates Biomedica’s exceptional system integration capabilities and adherence to global standards. More importantly, it signifies Taiwan’s solid position in AI medical imaging and smart healthcare interoperability, fully aligned with global advancements.
First Taiwan–Japan–Korea Joint Test in 20 Years — A Milestone for Asia-Pacific Medical Interoperability
Biomedica Achieves Dual Certification — Demonstrating Global AI Healthcare Competence
DICOM SWF (Scheduled Workflow)
This test focuses on the integrity and accuracy of the entire imaging workflow — from patient registration and image acquisition to report generation and data return. Biomedica collaborated with IHE Japan, DaiKon, and FUJIFILM in rigorous cross-verification tests and successfully passed all evaluation items, earning international interoperability certification.
FHIR MHD (Mobile Access to Health Documents)
This next-generation standard emphasizes cross-platform, real-time, and secure medical document exchange. Although Biomedica was not originally scheduled to participate in this category, its team proactively applied on-site to take on the challenge. Within a short timeframe, the engineers completed system integration, data format adjustments, and API connections — ultimately passing joint testing with DaiKon, IBM, and Soft Max. The success demonstrated the team’s technical agility and strong engineering depth in AI healthcare.
AIXA AI for Osteoporosis & Sarcopenia — Driving International Clinical Adoption
Biomedica revealed that its AIXA AI-powered medical imaging analysis system for osteoporosis and sarcopenia diagnosis is currently under regulatory review in Japan and South Korea. Using only a single X-ray image, AIXA can analyze bone density and muscle mass within six seconds, helping physicians quickly assess osteoporosis and sarcopenia risks, enabling early prevention and improving diagnostic efficiency.
With the successful results from the Taiwan–Japan–Korea joint testing, Biomedica is now poised to directly interface with hospital systems in Japan and South Korea, establishing an international clinical model for AI-based osteoporosis and muscle loss screening.